Jump to content

ConjuChem

From Wikipedia, the free encyclopedia
ConjuChem Biotechnologies Inc.
Company typePublic (TSX has Delisted this Stock)
IndustryBiotechnology
Headquarters,
Key people
Mark Perrin
ProductsDrug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC)
Number of employees
44[citation needed][needs update]
Websitewww.conjuchem.com

ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada[1] which is credited with inventing the experimental peptide hormone CJC-1295.[2][3]

It employs 45 people, 90% of whom are in research and development.[citation needed][needs update]

References

[edit]
  1. ^ "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
  2. ^ Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
  3. ^ "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Archived from the original on 18 June 2015. Retrieved 18 June 2015.
[edit]